Art. -Nr.: HY-N0049

Nuciferine

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Nuciferine is an antagonist at 5-HT_2A (IC₅₀=478 nM), 5-HT_2C (IC₅₀=131 nM), and 5-HT_2B (IC₅₀=1 μM), an inverse agonist at 5-HT₇ (IC₅₀=150 nM), a partial agonist at D₂ (EC₅₀=64 nM), D₅ (EC₅₀=2.6 μM) and 5-HT₆ (EC₅₀=700 nM), an agonist at 5-HT_1A (EC₅₀=3.2 μM) and D₄ (EC₅₀=2 μM) receptor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 475-83-2
Formel: C₁₉H₂₁NO₂
Molecular Weight:295.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Nuciferine Chemical Structure

CAS. Nr.: 475-83-2

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

5-HT_2C Receptor

131 nM (IC₅₀)

Schistosome

5-HT_1A Receptor

5-HT_2A Receptor

5-HT_2B Receptor

5-HT_2C Receptor

5-HT₇ Receptor

150 nM (IC₅₀)

5-HT_2A Receptor

478 nM (IC₅₀)

5-HT_2B Receptor

1 μM (IC₅₀)

5-HT₆ Receptor

700 nM (EC₅₀)

5-HT_1A Receptor

3.2 μM (EC₅₀)

D₂ Receptor

64 nM (EC₅₀)

D₄ Receptor

2 μM (EC₅₀)

D₅ Receptor

2.6 μM (EC₅₀)

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
B16-4A5	IC₅₀	15.8 μM Compound: 2	Inhibition of melanogenesis in mouse B16-4A5 cells after 72 hrs by spectrophotometry Inhibition of melanogenesis in mouse B16-4A5 cells after 72 hrs by spectrophotometry	[PMID: 23270663]

In Vitro

Nuciferine is a partial agonist at DD₂ receptor with an activity (E_max=67% of dopamine) similar to aripiprazole (E_max=50% of dopamine). In line with its partial agonist activity, Nuciferine inhibited dopamine-induced activation of G_i with a potency similar to clozapine (Nuciferine K_B=62 nM; Clozapine K_B=20 nM) as determined via Schild regression analysis^[1]. The natural product Nuciferine acts as an effective inhibitor of adult worm motility. Nuciferine is effective at inhibiting both basal and 5-HT evoked motility of adult schistosomes. Nuciferine inhibits Sm.5HTR_L and schistosomule with 0.24±0.04 and 0.62±0.22 μM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In rodent models relevant to antipsychotic drug action, Nuciferine blocks head-twitch responses and discriminative stimulus effects of a 5-HT_2A agonist, substituted for clozapine discriminative stimulus, enhanced amphetamine induced locomotor activity, inhibited phencyclidine (PCP)-induced locomotor activity, and rescued PCP-induced disruption of prepulse inhibition without induction of catalepsy. In the presence of 1 or 3 mg/kg Nuciferine, cumulative PCP doses produce similar substitution to PCP alone. In the clozapine-trained animals, a dose-dependent substitution for 1.25 mg/kg clozapine is seen at 10 mg/kg Nuciferine (80.63% drug lever responding), with an ED₅₀ value of 5.42 mg/kg (95% CI 3.09-9.48 mg/kg) while the lower doses tested (0.1 mg/kg-3 mg/kg) fails to produce substitution for clozapine’s discriminative cue. In addition to a high percentage of responding on the clozapine-appropriate lever, 10 mg/kg Nuciferine also produces significant rate suppression as compared to vehicle control points (p<0.001)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 475-83-2
Appearance Solid
Molecular Weight 295.38
Formel C₁₉H₂₁NO₂
Color White to off-white
SMILES

CN1CCC2=CC(OC)=C(OC)C3=C2[C@@]1([H])CC4=CC=CC=C34
Structure Classification
- Alkaloids
- Isoquinoline Alkaloids
- Alkaloids
- Aporphine Alkaloids
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All Cell Proliferation/Viability AssayWBIFHistological Imaging/StainingELISA

Sort by:

Journal Impact Factor

J Adv Res

Nuciferine inhibits pressure overload-induced cardiac remodeling by activating the SENP1-ACSL4-ferroptosis axis. [Abstract]

2025 Aug 18:S2090-1232(25)00635-6. PMID: 40835001

Nuciferine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug 18:S2090-1232(25)00635-6. [Abstract]

Quantitative analysis of survival rates after treatment with different concentrations of Nuciferine (NF) (0.5, 1, 2, 5, 10, 20, 50, 100 μM) and Erastin in NRCMs.

Nuciferine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug 18:S2090-1232(25)00635-6. [Abstract]

Representative Western blotting images and quantitative results of TFR1, ACSL4, PTGS2, NOX1, FTH1 and GPX4 expression in left ventricular tissues treated with Nuciferine (NF)

Nuciferine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug 18:S2090-1232(25)00635-6. [Abstract]

Representative images of DCFH-DA and JC-1 staining, and quantification of ROS fluorescence and JC-1 ratio in NRCMs treated with Nuciferine (NF).

Nuciferine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug 18:S2090-1232(25)00635-6. [Abstract]

Representative images of H&E staining, WGA staining and PSR staining in left ventricular sections treated with Nuciferine (NF) (30 mg/kg, p.o.).

Nuciferine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug 18:S2090-1232(25)00635-6. [Abstract]

Quantification of heart tissue levels of IL-6, IL-1b, and TNF-a treated with Nuciferine (NF) (30 mg/kg, p.o.).
Phytomedicine

Nuciferine ameliorates steroid-induced osteonecrosis of the femoral head by inhibiting BMSCs ferroptosis via HIF-1α. [Abstract]

2026 Jun:155:158070. PMID: 41861683
J Agric Food Chem

Nuciferine Alleviates High-Fat Diet- and ApoE-/--Induced Hepatic Steatosis and Ferroptosis in NAFLD Mice via the PPARα Signaling Pathway. [Abstract]

2024 Nov 6;72(44):24417-24431. PMID: 39445611
Int Immunopharmacol

Nuciferine improves random skin flap survival via TFEB-mediated activation of autophagy-lysosomal pathway. [Abstract]

2023 Jun:119:110204. PMID: 37126988
Nutr Metab

Lotus leaf extract inhibits ER- breast cancer cell migration and metastasis. [Abstract]

2021 Feb 18;18(1):20. PMID: 33602253
J Funct Foods

August 2022, 105182.
Fish Shellfish Immunol

Nuciferine supplement improved intestinal function and inflammatory response in juvenile large yellow croaker (Larmichthys crocea) fed diets with high palm oil level. [Abstract]

2025 Oct:165:110535. PMID: 40617415
Mol Pharmacol

G α Protein Signaling Bias at Serotonin 1A Receptor. [Abstract]

2023 Nov;104(5):230-238. PMID: 37567783

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 5 mg/mL (16.93 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3855 mL

16.9273 mL

33.8547 mL

5 mM

0.6771 mL

3.3855 mL

6.7709 mL

10 mM

0.3385 mL

1.6927 mL

3.3855 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.11 mg/mL (3.76 mM); Clear solution

This protocol yields a clear solution of ≥ 1.11 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.11 mg/mL (3.76 mM); Clear solution

This protocol yields a clear solution of ≥ 1.11 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.11 mg/mL (3.76 mM); Clear solution

This protocol yields a clear solution of ≥ 1.11 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (11.1 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Kinase Assay^[1]

For affinity determination, Nuciferine is subjected to primary radioligand binding assays tested at a single 10 μM concentration to displace 50% of the radioligand at a given receptor target. If a more than 50% of the radioligand is displaced, Nuciferine is selected for a secondary binding assay tested at 11 concentrations in triplicate in competition with the radioligand to generate an IC₅₀ and K_i. Binding assays are performed in 96-well plates with 125 μL per well in appropriate binding buffer using radioligand at or near the K_d. Plates are incubated at room temperature in the dark for 90 min. Reactions are stopped by vacuum filtrations onto 0.3% polyethyleneimine soaked 96-well filter mats using a 96-well Filtermate harvester, followed by at least three washes of cold wash buffer. Scintillation cocktail is melted onto dried filters and radioactivity is counted using a Wallac Trilux Microbeta^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Cells are plated into 48-well plates one day before uptake is performed. Cells are washed with 0.5 mL uptake buffer (4 mM Tris, 6.25 mM HEPES, 120 mM NaCl, 5 mM KCl, 1.2 mM CaCl₂, 1.2 mM MgSO₄, 5.6 mM D-glucose, 1.7 mM ascorbic acid, and 1 μM pargyline, pH 7.4). Cells are incubated with 225 μL uptake buffer with or without the indicated concentration of Nuciferine for 15 minutes. After incubation, 25 μL uptake buffer containing ³H-DA and DA is added for a final concentration of 20 nM ³H-DA and 1 μM DA. Cells are incubated at 37°C for 20 minutes or for the time indicated. Nonspecific uptake is determined in the presence of 10 μM nomifensine. Uptake is terminated by aspirating uptake buffer and washing each well twice with 0.5 mL ice-cold uptake buffer. Cells are lysed in 0.1 N NaOH and transferred to vials containing 3 mL scintillation cocktail. Radioactivity is quantitated using a Beckman LS6500 counter. Data are analyzed in Graph Pad Prism 5.0^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Adult male NIH Swiss mice weighing approximately 25 g are used. Mice are injected with either Nuciferine (1, 3, or 10 mg/kg, i.p.) or vehicle, n=4 mice/condition. Fifteen minutes later, mice are injected with 1 mg/kg DOI (i.p.) and immediately placed in an observation chamber (new cage without bedding). Head-twitches (operationally defined as a rapid rotational jerk of the head that can be distinguished from species-appropriate grooming or scratching behaviors) are counted for 20 minutes in 5 minute bins. For the time-course study, mice are pretreated with 3.0 mg/kg Nuciferine (i.p.) at 60, 45, 30, 15, or 0 minutes (co-injection) prior to the 1.0 mg/kg DOI (i.p.) injection, and head-twitches are counted as described above. In one experiment, mice (n=4 per condition) are pretreated with an injection (s.c.) of 3.0 mg/kg Nuciferine or vehicle 15 minutes prior to 1.0 mg/kg DOI injection (i.p.) and head-twitches are counted as described above. All experiments are performed by 3 observers, with 2 observers blinded to the experimental conditions which are evenly distributed. Power analyses are performed with the resulting data. The two highest doses of Nuciferine tested (10 and 3 mg/kg), had 0.96 and 0.88 power to detect significance (α=0.05). As these experiments are performed blinded and in distinct mice, further replication is not performed.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Farrell MS, et al. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. PLoS One. 2016 Mar 10;11(3):e0150602. [Content Brief]

[2]. Chan JD, et al. Pharmacological profiling an abundantly expressed schistosome serotonergic GPCR identifies nuciferine as a potent antagonist. Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):364-370. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3855 mL	16.9273 mL	33.8547 mL	84.6367 mL
	5 mM	0.6771 mL	3.3855 mL	6.7709 mL	16.9273 mL
	10 mM	0.3385 mL	1.6927 mL	3.3855 mL	8.4637 mL
	15 mM	0.2257 mL	1.1285 mL	2.2570 mL	5.6424 mL

Keywords

Nuciferine

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Nuciferine

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

Natural Product Library

Medicine Food Homology Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Alkaloids Library

Antiparasitic Compound library

Anti-Parkinson's Disease Compound Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

5-HT Receptor Compound Library

Coagulation and Anti-coagulation Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Dopamine Receptor Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Nuciferine

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen

Alle Dopamine Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Nuciferine Related Classifications

Art. -Nr.: HY-N0049